Earnings Briefs: Biogen, Celgene, Actelion, Cubist
Executive Summary
Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.
You may also be interested in...
R&D News In Brief: Otezla Disappoints But Dupilumab Doesn’t, Astellas Files Antifungal And NovoSeven Adds Indication
POSTURE study will continue unchanged for Celgene’s PDE-4 inhibitor due to meaningful efficacy seen in a pre-specified subgroup with early-stage disease. Astellas submits an NDA for broad-spectrum antifungal isavuconazole in invasive aspergillosis and invasive mucormycosis. Other drug development news, in brief …
Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected
FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.
Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.